D&D Pharmatech Announces Launch of Valted Seq Subsidiary Focusing on Discovery of Neurodegenerative Disease Pathways and Biomarkers to Support Development of New Therapeutics and Diagnostics
GYEONGGI-DO, South Korea & GAITHERSBURG, Md.–(BUSINESS WIRE)–D&D Pharmatech, Inc. (D&D), a clinical-stage biotechnology company focused on development and commercialization of revolutionary medicines, today announced the launch of their fourth subsidiary, Valted Seq. D&D Pharmatech is also the parent company of Neuraly, Precision Molecular, and Theraly Fibrosis. Read More
URL link to full story
https://www.businesswire.com/news/home/20200909005093/en/DD-Pharmatech-Announces-Launch-Valted-Seq-Subsidiary
Media Contact
Christine Quern CBQ Communications
617-650-8497